Delcath Systems Inc (DCTH)

[AugustStockInformer]

See if Delcath keeps its promises when reviewing this old interview:
https://www.twst.com/interview/richard-taney-delcath-systems-inc-dcth-2

TWST: What else is in the pipeline? Is liver cancer your primary focus?

Mr. Taney: Liver disease is our primary focus and that focus can be even further sharpened to the treatment of cancers of the liver. We currently have two Phase III trials testing melphalan and doxorubicin in high doses with our system for a number of cancers of the liver. Other applications for the Delcath System involve the ability to work with a variety of drugs in the treatment of a
variety of cancers and liver diseases.